MYGNMyriad Genetics, Inc.

NAS · US · Healthcare · Diagnostics & Research · myriad.com

3.200USD+0.31%Mkt Cap: 306.08M $P/E: —3d ago

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides …

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap306.08M $

Enterprise Value157.29M $

Revenue (TTM)557.00M $

Gross Profit576.60M $

Net Income (TTM)-365.90M $

Revenue/Share7.452 USD

Last Price3.200 USD

Fiscal Year EndDec 2025

MR QuarterDec 2020

Employees2.7K

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISINUS62855J1043

Valuation

P/E (Trailing)—

P/E (Forward)-6.05

PEG1.24

EV/EBITDA-1.41

EV/Revenue0.28

P/S0.55

P/B1.01

EPS (TTM)-1.19

EPS (Forward)-0.53

52W Range

2.7408% of range8.590

52W High8.590 USD

52W Low2.740 USD

Profitability

Gross Margin69.93%

Oper. Margin-21.41%

EBITDA Margin-20.09%

Profit Margin-44.38%

ROE-99.43%

ROA-51.78%

Growth

Revenue Growth-20.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF1.80M $

CapEx (TTM)27.40M $

FCF Margin-8.27%

FCF Yield-15.05%

Net Debt-150.70M $

Net Debt/EBITDA1.35

Balance Sheet

Debt/Equity0.57

Current Ratio2.67

Quick Ratio1.65

Book Value/Sh3.179 USD

Cash/Share1.576 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split2:1

Split DateMar 26, 2009

Analyst Consensus

Rating3.0 (Hold)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)3.956 USD

Upside (mean)+23.6%

Target Range3.000 USD – 5.450 USD

$3.000+23.6% to mean$5.450

# Analysts8

Ownership

Shares Out.95.65M

Float87.09M

Insiders3.97%

Institutions97.05%

Short Interest

Short Ratio5.0d

Short % Float9.10%

Short % Out.8.88%

Shares Short8.50M

Short (prev mo.)8.56M

Technical

SMA 504.744 (-32.5%)

SMA 2005.254 (-39.1%)

Beta1.64

S&P 52W Chg18.16%

Avg Vol (30d)2.03M

Avg Vol (10d)1.62M

Technical Indicators

RSI (14)32.1

MACD-0.5656

MACD Signal-0.5520

MACD Hist.-0.0136

BB Upper5.983 USD

BB Middle3.824 USD

BB Lower1.664 USD

BB Width112.95%

ATR (14)0.2853 USD

Vol Ratio (20d)0.49x